betaxolol has been researched along with Paronychia in 3 studies
Paronychia: An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia." | 8.02 | Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. ( Chen, CB; Chen, KH; Chen, MJ; Chung, WH; Fang, YF; Hsu, PC; Ko, HW; Ko, YS; Li, SH; Lin, YJ; Lu, CW; Shih, FY; Su Pang, JH; Tseng, LC; Wang, CL; Wang, TY; Wu, CE; Yen, CF, 2021) |
| "Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0." | 7.96 | Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. ( Chi, CC; Chung, WH; Hsu, CK; Ko, YS; Lee, CN; Lu, CW; Pang, JS; Wang, CL; Wang, CW; Yang, HS; Yen, CF, 2020) |
| "Preventively using topical betaxolol can significantly decrease the incidence, VAS score, and grading of EGFR-TKI-induced paronychia." | 4.02 | Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. ( Chen, CB; Chen, KH; Chen, MJ; Chung, WH; Fang, YF; Hsu, PC; Ko, HW; Ko, YS; Li, SH; Lin, YJ; Lu, CW; Shih, FY; Su Pang, JH; Tseng, LC; Wang, CL; Wang, TY; Wu, CE; Yen, CF, 2021) |
| "Data from a series of 35 non-small cell lung cancer cases suffering from EGFR inhibitor-induced paronychia with pyogenic granuloma-like lesions of digits treated with betaxolol 0." | 3.96 | Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. ( Chi, CC; Chung, WH; Hsu, CK; Ko, YS; Lee, CN; Lu, CW; Pang, JS; Wang, CL; Wang, CW; Yang, HS; Yen, CF, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yen, CF | 3 |
| Hsu, CK | 2 |
| Yang, HS | 1 |
| Lee, CN | 1 |
| Chi, CC | 1 |
| Chung, WH | 2 |
| Wang, CL | 2 |
| Pang, JS | 1 |
| Wang, CW | 1 |
| Ko, YS | 2 |
| Lu, CW | 3 |
| Wang, TY | 1 |
| Chen, KH | 1 |
| Wu, CE | 1 |
| Hsu, PC | 1 |
| Fang, YF | 1 |
| Li, SH | 1 |
| Ko, HW | 1 |
| Tseng, LC | 1 |
| Shih, FY | 1 |
| Lin, YJ | 1 |
| Chen, MJ | 1 |
| Chen, CB | 1 |
| Su Pang, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitor-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study[NCT05165082] | 8 participants (Actual) | Interventional | 2021-12-21 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for betaxolol and Paronychia
| Article | Year |
|---|---|
Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
Topics: Administration, Topical; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Ant | 2020 |
Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study.
Topics: Antineoplastic Agents; Betaxolol; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studi | 2021 |
Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors.
Topics: Administration, Topical; Afatinib; Betaxolol; ErbB Receptors; Female; Follow-Up Studies; Granuloma, | 2018 |